Overview

Safety and Tolerability Analysis of Combining Desmopressin With Docetaxel for the Treatment of Castration-Resistant Prostate Cancer

Status:
Unknown status

Trial end date:
2020-10-01

Target enrollment:

Participant gender:

Summary

This is a single site, prospective, Phase 1 pilot trial intended to evaluate the safety and tolerability of adding one IV dose of Desmopressin to CRPC subjects at least 30 minutes prior to commencing standard IV Docetaxel treatment7,8.

Phase:

Early Phase 1

Details

Lead Sponsor:

Sunnybrook Health Sciences Centre

Collaborator:

Sunnybrook Research Institute

Treatments:

Deamino Arginine Vasopressin
Docetaxel